Natalia Bartolommei, Francesco Casamassima, Laura Pensabene, Federica Luchini, Antonella Benvenuti, Antonello Di Paolo, Luca Cosentino, Mauro Mauri, Lorenzo Lattanzi
{"title":"齐拉西酮作为氯氮平治疗重度双相患者的辅助疗法。","authors":"Natalia Bartolommei, Francesco Casamassima, Laura Pensabene, Federica Luchini, Antonella Benvenuti, Antonello Di Paolo, Luca Cosentino, Mauro Mauri, Lorenzo Lattanzi","doi":"10.1155/2014/904829","DOIUrl":null,"url":null,"abstract":"<p><p>Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course. </p>","PeriodicalId":14749,"journal":{"name":"ISRN Psychiatry","volume":"2014 ","pages":"904829"},"PeriodicalIF":0.0000,"publicationDate":"2014-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/904829","citationCount":"2","resultStr":"{\"title\":\"Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine.\",\"authors\":\"Natalia Bartolommei, Francesco Casamassima, Laura Pensabene, Federica Luchini, Antonella Benvenuti, Antonello Di Paolo, Luca Cosentino, Mauro Mauri, Lorenzo Lattanzi\",\"doi\":\"10.1155/2014/904829\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course. </p>\",\"PeriodicalId\":14749,\"journal\":{\"name\":\"ISRN Psychiatry\",\"volume\":\"2014 \",\"pages\":\"904829\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2014/904829\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ISRN Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2014/904829\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2014/904829","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine.
Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
